In a report released today, Michael Matson from Needham maintained a Hold rating on InMode. The company’s shares closed yesterday at $15.89.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific, TransMedics Group, and Penumbra. According to TipRanks, Matson has an average return of -3.4% and a 41.16% success rate on recommended stocks.
InMode has an analyst consensus of Moderate Buy, with a price target consensus of $17.50.
INMD market cap is currently $1.05B and has a P/E ratio of 6.44.
Read More on INMD:
Disclaimer & DisclosureReport an Issue
- Needham medtech & diagnostics analysts hold analyst/industry conference call
- Midday Fly By: Delta beats, PepsiCo names new CFO
- InMode sees Q3 revenue $92.5M-$93M, consensus $88.05M
- InMode backs FY25 revenue view $365M-$375M, consensus $368.45M
- InMode Ltd. Sees Partial Dismissal in Shareholder Class Action
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/AI%20(artificial%20intelligence)/Businessman%20touching%20the%20brain%20working%20of%20Artificial%20Intelligence%20(AI)%20Automation%20by%20Suttiphong%20Chandaeng%20via%20Shutterstock.jpg)
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
